-transparent.png){kind=logo}
A double-blind, placebo-controlled trial of topical 5% acyclovir (ACV) in polyethylene glycol (PEG) was carried out among 208 patients who had an episode of herpes simplex labialis. Patients who were treated with ACV had a greater decrease in median titers of virus in lesions between the first and second visits to the clinic than did patients who were treated with placebo (-1.5 log pfu [plaque-forming units] vs. -0.2 log pfu; P = 0.04). The antiviral effect occurred in the subgroup of patients who entered the study 0-8 hr after the onset of lesions. No differences were noted in the remaining patients who began treatment 9-25 hr after onset. An examination of the subgroup who had virus-positive specimens before treatment revealed prominent and more statistically significant virologic differences between treatment groups. No clinical benefit from treatment with ACV was observed; however, the present study describes the first antiviral effect of topical treatment for recurrent herpes labialis and identifies treatment strategies for future studies.
S L Spruance, and
L E Schnipper, and
J C Overall, and
E R Kern, and
B Wester, and
J Modlin, and
G Wenerstrom, and
C Burton, and
K A Arndt, and
G L Chiu, and
C S Crumpacker
July 1982,
The American journal of medicine,
S L Spruance, and
L E Schnipper, and
J C Overall, and
E R Kern, and
B Wester, and
J Modlin, and
G Wenerstrom, and
C Burton, and
K A Arndt, and
G L Chiu, and
C S Crumpacker
May 1983,
British medical journal (Clinical research ed.),
S L Spruance, and
L E Schnipper, and
J C Overall, and
E R Kern, and
B Wester, and
J Modlin, and
G Wenerstrom, and
C Burton, and
K A Arndt, and
G L Chiu, and
C S Crumpacker
February 1990,
The Journal of infectious diseases,
S L Spruance, and
L E Schnipper, and
J C Overall, and
E R Kern, and
B Wester, and
J Modlin, and
G Wenerstrom, and
C Burton, and
K A Arndt, and
G L Chiu, and
C S Crumpacker
July 1985,
Clinical pharmacology and therapeutics,
S L Spruance, and
L E Schnipper, and
J C Overall, and
E R Kern, and
B Wester, and
J Modlin, and
G Wenerstrom, and
C Burton, and
K A Arndt, and
G L Chiu, and
C S Crumpacker
January 1993,
Journal of medical virology,
S L Spruance, and
L E Schnipper, and
J C Overall, and
E R Kern, and
B Wester, and
J Modlin, and
G Wenerstrom, and
C Burton, and
K A Arndt, and
G L Chiu, and
C S Crumpacker
April 1996,
BMJ (Clinical research ed.),
S L Spruance, and
L E Schnipper, and
J C Overall, and
E R Kern, and
B Wester, and
J Modlin, and
G Wenerstrom, and
C Burton, and
K A Arndt, and
G L Chiu, and
C S Crumpacker
March 1980,
JAMA,
S L Spruance, and
L E Schnipper, and
J C Overall, and
E R Kern, and
B Wester, and
J Modlin, and
G Wenerstrom, and
C Burton, and
K A Arndt, and
G L Chiu, and
C S Crumpacker
September 1988,
JAMA,
S L Spruance, and
L E Schnipper, and
J C Overall, and
E R Kern, and
B Wester, and
J Modlin, and
G Wenerstrom, and
C Burton, and
K A Arndt, and
G L Chiu, and
C S Crumpacker
September 1983,
The British journal of dermatology,
S L Spruance, and
L E Schnipper, and
J C Overall, and
E R Kern, and
B Wester, and
J Modlin, and
G Wenerstrom, and
C Burton, and
K A Arndt, and
G L Chiu, and
C S Crumpacker
June 1982,
The Medical letter on drugs and therapeutics,
